Sulphonylureas stimulate insulin secretion from pancreatic β-cells primarily by closing ATP-sensitive K + channels in the β-cell plasma membrane. The mechanism of channel inhibition by these drugs is unusually complex. As direct inhibitors of channel activity, sulphonylureas act only as partial antagonists at therapeutic concentrations. However, they also exert an additional indirect inhibitory effect via modulation of nucleotidedependent channel gating. In this review, we summarize current knowledge and recent advances in our understanding of the molecular mechanism of action of these drugs.
Introduction
Sulphonylurea drugs have been used for over 60 years to treat type 2 diabetes [1] . These drugs share a common mechanism of action, which is also the case for the previously developed anti-hyperglycaemic drugs, glinides [2] . Their primary target is the ATP-sensitive potassium (K ATP ) channel which controls plasma membrane potential in the pancreatic β-cells [3] . Binding of sulphonylureas to K ATP channel induces channel closure [4] . This causes membrane depolarization, which activates voltage-dependent Ca 2 + channels in the β-cell plasma membrane and the resulting Ca 2 + influx triggers Ca 2 + -dependent insulin granule exocytosis. In addition to their action on the K ATP channel, sulphonylureas can also stimulate insulin secretion independently of changing the membrane potential via interactions with proteins within the exocytotic pathway [5, 6] .
The B-cell K ATP channel and sulphonylureas
The β-cell K ATP channel couples glucose metabolism to β-cell electrical activity. Gating (opening and closing) of these channels is primarily determined by intracellular concentrations of adenosine nucleotides (nts). Under Mg 2 + -free conditions, unchelated ATP (and ADP) inhibits K ATP channels through binding to the pore-forming subunit of the channel complex; it is important to note that this inhibitory ligand-binding site does not discriminate between the chelated and unchelated forms of ATP. On the contrary, chelated MgADP (or MgATP) stimulates channel activity through specific interaction with the nt-binding domains of a regulatory subunit of the channel [(sulphonylurea receptor Key words: ABCC8, diabetes, KATP channels, Kir6.2, SUR1. Abbreviations: ABC, ATP-binding cassette; KATP, ATP-sensitive potassium channel; NBD1/2, ntbinding domain 1/2; NBS1/2, nt-binding site 1/2; ND, neonatal diabetes; nt, nucleotides; PO, open probability; SUR, sulphonylurea receptor; TM, transmembrane domain. 1 To whom correspondence should be addressed (email peter.proks@dpag.ox.ac.uk).
(SUR)], counteracting these nts' simultaneous inhibitory effect at the channel pore [7] .
The K ATP channel is a hetero-octameric complex composed of four Kir6.2 subunits and four SUR subunits [8] . Kir6.2 (KCNJ11) is a member of the inwardly rectifying Kchannel family; it possesses a potassium-selective pore and an inhibitory site for (Mg)ATP [9] . SURs are members of the C subfamily of the ABC (ATP-binding cassette) superfamily [10] . There are three isoforms of the SUR: ABCC8/SUR1 is expressed in pancreas and neurons, ABCC9/SUR2A in skeletal and cardiac muscle and a splice variant of ABCC9, called SUR2B, in smooth muscle and brain. The major regulatory role of SURs is to mediate stimulation by Mgadenosine nts via their two nt-binding domains: nt-binding domain 1 (NBD1) and nt-binding domain 2 (NBD2). Nt binding to SURs causes head-to-tail dimerization of the NBDs and formation of two nt-binding sites [NBS1 (ntbinding site 1) and NBS2 (nt-binding site 2)] within the dimer interface. NBS2 possesses greater ATPase activity than NBS1; and its occupancy by MgADP stimulates K ATP channel activity [11] . Available data indicate that MgATP promotes channel opening only via its hydrolysis to MgADP [11, 12, 13] ; in this aspect, regulation of K ATP channel activity by NBSs of SUR differs from that of other ABC proteins such as CFTR (cystic fibrosis transmembrane conductance regulator) (ABCC7) or P-gp (P-gap, ABCB1) where conformational changes induced by MgATP binding [14] [15] [16] [17] result in promotion of channel opening (CFTR) or stimulation of drug transport (P-gp).
K ATP channels possess both high-affinity-and lowaffinity-binding sites for sulphonylureas and glinides. The precise locations of these binding sites are currently unknown. The high affinity site involves intracellular loops of SUR between transmembrane domains (TMs) 5 and 6 [18] and TMs 15 and 16 [19] . N-terminus of Kir6.2 is also involved in binding of the sulphonylurea glibenclamide and the glinide repaglinide [18, 20, 21] .
Direct inhibitory effect of sulphonylureas
Consistent with the existence of two distinct binding sites, sulphonylurea concentration-inhibition curve for K ATP channels measured in excised patches in the absence of nts is biphasic ( Figure 1A) . The low-affinity block resides on Kir6.2 subunit; the high-affinity site is present only when Kir6.2 is co-expressed with SUR [22] . The low-affinity site is of no clinical relevance as it is occupied only at concentrations much higher than those found in the plasma of patients treated with sulphonylureas [23] . In the absence of intracellular nts, the maximal extent of high-affinity inhibition is only 50 %-80 %, depending on the type of sulphonylurea [2, 4] . Thus, sulphonylureas bound to the high-affinity site act only as partial antagonists so that the channel remains open for a substantial fraction of time when the high-affinity-binding sites are fully occupied.
In excised patches, K ATP channels undergo rundown, spontaneous decline of channel activity, which consists of a fast, dramatic decrease in current during the first minute after patch excision followed by a subsequent slow phase with a mild decrease in current [24] . Figure 1 (B) illustrates how rundown may affect the direct inhibitory effect of sulphonylureas; it depicts the dependence of the fraction of drug-resistant current on single channel open probability (P O ) for high-affinity gliclazide inhibition; simulated with a simple concerted gating model [25] . The value of intrinsic P O before rundown (or in the intact cell) is unknown; however, it is likely to be much higher than that during the slow phase of rundown during which experiments are usually conducted (P O ∼0.2-0.4) [24] . Thus, it is important to note that the efficacy of direct sulphonylurea inhibition of K ATP channels in vivo is likely to be lower than that obtained from data on excised patches.
Indirect inhibitory effect of sulphonylureas
K ATP channel activity inside intact pancreatic β-cells is quite low (P O < 0.2) [13] due to the dominant inhibitory effect of large intracellular ATP concentrations. Assuming similar sulphonylurea-binding affinity for nt-bound and nt-free states of the channel, these drugs would produce only partial inhibition of K ATP current in intact β-cells (e.g., ∼80 % for gliclazide in Figure 1B ). Yet, when sulphonylurea drugs are applied to whole-cell K ATP currents in intact cells, the highaffinity inhibition is virtually complete ( Figure 1A ) [2, 4] .
Multiple studies demonstrated that the maximal extent of high-affinity sulphonylurea inhibition of K ATP channels is enhanced in the presence of MgADP in excised patches [2, 4, 22, [26] [27] [28] [29] [30] and studies of this effect eventually led to a postulation of a second, indirect action of sulphonylureas on K ATP channel gating ( Figures 1C and 1D ) [2, 4, 22] . As well as directly inhibiting the channel, sulphonylurea binding to the high-affinity site also suppresses the activatory effect of MgADP (or MgATP); this in turn 'unmasks' the inhibitory effect of the nt which is then combined with that of the sulphonylurea ( Figures 1A, 1C and 1D ).
More recently, the mechanism of sulphonylureas on K ATP channel activation by Mg-nts was examined in more detail using K ATP channels with a point mutation G334D in the Kir6.2 subunit, Kir6.2-G334D/SUR1 channels ( Figure 2) [30]. This mutation severely impairs the inhibitory effect of ATP at Kir6.2 [30-32] which allows studying the properties of Mg-nt activation in isolation from nt inhibition. As shown in Figures 2C and 2D , in the presence of 30 μM gliclazide, concentration-activation curves for both MgADP and MgATP on Kir6.2-G334D/SUR1 channels are dramatically shifted to the right. In addition, the drug also appears to reduce the maximal extent of the activatory effect of the nts. Detailed analysis of data suggest that the drug both reduces nt binding to SUR1 and impairs the efficacy with which nt binding is transduced into pore opening [30] .
Interestingly, a similar effect to gliclazide on MgADP binding and transduction was observed for mutations of either of the Walker A lysines in the catalytic site of the NBS1 or NBS2 of SUR1 [30] . In contrast, these mutations did not appear to impair MgATP binding. This is consistent with a previous finding that mutations of the Walker A lysines reduce, but do not affect K m values of MgATP hydrolysis in SUR1 [33] . In addition to altering the maximal extent of high-affinity sulphonylurea block, Mg-nts also increase the value of IC 50 for high-affinity drug inhibition [4, 25] . This can be attributed to a reciprocal interaction between the two compounds, displacement of sulphonylurea binding by the nt, as previously demonstrated by Hambrock et al. [34] .
Unlike for SUR1-containing channels, Mg-nt activation of K ATP channels with the SUR2A regulatory subunit is unaffected by sulphonylureas [25] and the maximal extent of high-affinity sulphonylurea inhibition of SUR2A-containing channels is reduced, rather than increased in the presence of the nt [2, 25, 35] . This may be a contributing factor to a low occurrence of cardiac side effects of sulphonylureas. Reduced sulphonylurea efficacy in this case may be an indirect effect of Mg-nts on channel gating ( Figure 1B ).
Implications for treatment of neonatal diabetes
The fact that efficient sulphonylurea inhibition of K ATP channels requires the inhibitory effects of nts to be intact is of special significance for treating neonatal diabetes (ND) caused by mutations in the K ATP channel [36] .
ND mutations are found in both Kir6.2 and SUR1 subunits of the K ATP channel [36, 37] . Most of these mutations impair channel inhibition by ATP either directly, via reducing ATP binding to Kir6.2, or indirectly, via impairing channel gating [36, 37] . The latter mutations stabilize the open state of the channel and thus impair channel ability to close both in the absence and in the presence of nts. Both these defects also affect sulphonylurea efficacy to close the K ATP channel; mutations that reduce ATP binding to Kir6.2 impair (A) Gliclazide concentration-inhibition curves for wild-type β-cell K ATP currents in excised patch (nt-free solution) and in intact cell (nt present), as indicated. The data is plotted as the current measured in the presence of the drug (I) expressed as a fraction of current in its absence (I C ). The fitting parameters were published previously in Proks et al. [4] . The line for data obtained for excised patches is drawn according to equation:
where IC 50,1 = 51 nM and IC 50,2 = 3.1 mM are the half-maximal inhibitory concentrations at the high-and low-affinity sites respectively; h 1 = 1.0 and h 2 = 1.0 are the Hill coefficients for the high-and low-affinity sites respectively; and a = 0.4 is the fraction of sulphonylurea-resistant current when all high-affinity sites are occupied. The line for data obtained for intact cell is drawn according to the below equation [4] : the indirect inhibitory effect of sulphonylureas whereas mutations that impair ATP inhibition indirectly via affecting channel gating reduce both direct and indirect inhibitory effect of sulphonylureas [25, 38, 39] .
The ability of sulphonylureas to treat patients with ND caused by mutations in K ATP channels depends on the severity of functional defect caused by these mutations. This is illustrated in Figure 3 (intermediate DEND syndrome; ND with developmental delay and epilepsy); [40] . In the presence of 100 μM MgATP ( Figure 3A, filled symbols) , suppression of MgATP activation by gliclazide unmasks inhibitory effect of the nt which results in ∼50 % reduction in the gliclazide-resistant current (since 100 μM is close to IC 50 for the inhibitory effect of ATP).
Note that there is also a small increase in IC 50 for gliclazide block in the presence of MgATP attributable to displacement of the drug by the nt discussed above.
ATP-binding mutation G334D almost completely abolishes the inhibitory effect of ATP [31, 32] ; patients with this mutation have the most severe form of ND with developmental delay and epilepsy (DEND syndrome) [32] . Since the inhibitory effect of ATP is virtually absent from these channels, maximal extent of high-affinity sulphonylurea inhibition of K ATP channels with this mutation is not enhanced by MgATP, even at a physiological concentration of the nt (1 mM; Figures 3C, 3E and 3F) . In contrast, channels with mutation R201C are almost completely inhibited with 1 mM MgATP in the presence of the sulphonylurea (Figure 3F ). This explains why sulphonylureas can be used to treat ND in patients with R201C but not G334D mutation [25, 41] .
Intermediate DEND syndrome mutation V59M [40] impairs gating of the channel and thus suppresses the direct inhibitory effect of gliclazide ( Figures 1B and 3B , open circles). However, the maximal extent of the sulphonylurea inhibition is greatly enhanced in the presence of 100 μM MgATP as the drug unmasks substantial inhibitory effect of the nt at Kir6.2 (IC 50 for the inhibitory effect of ATP is 62 μM) [25] . Thus, although inhibition by sulphonylurea alone is poor, these channels can be effectively blocked by the drug in the presence of physiological concentrations of ATP (1 mM, Figure 3F ). This is not the case for mutation I296L, which is only partially blocked by gliclazide even in the presence of 3 mM of MgATP ( Figure 3D ). This mutation causes very strong gating defect that results in DEND syndrome; unlike for V59M, patients with this mutation cannot be treated with sulphonylureas [42] .
In addition to the defects in ATP inhibition, some mutations in SUR cause ND by enhancing channel activation by Mg-nts [39] . Available data suggest that mutations discovered so far in this category may have either no effect or cause only small reduction in the indirect block of sulphonylureas [39] , which is probably mediated via displacement of the drug from SUR1 by Mg-nt binding to NBS2 [43] .
Concluding remarks
Effective inhibition of β-cell K ATP channels by sulphonylureas requires co-operation from adenosine nts, which are major intracellular modulators of these channels. The same is true for glinides such as repaglinide [44] . Interestingly, recent data indicate that the collaboration between nts and sulphonylureas extends beyond the K ATP channel. Drug-induced stimulation of insulin exocytosis via Epac2 (cAMP-activated guanine-nt exchange factor). It has recently been demonstrated that binding of sulphonylureas to this protein requires cAMP [45] . Understanding of the molecular mechanisms of action of sulphonylureas thus underlines the importance of studying drug effects within the context of the native cellular environment. 
